Vulvar Paget Disease: From Empirical Management to Emerging Precision Oncology Strategies

Authors: Corrado, Giacomo; Pomati, Giulia; Palluzzi, Eleonora; Manna, Gaia; Fragomeni, Simona Maria; Federico, Alex; Vizzielli, Giuseppe; Perrone, Anna Myriam; Lanzetta, Gaetano; Fagotti, Anna; Garganese, Giorgia

Source journal: Current oncology reports (2026-11-19)

DOI: 10.1007/s11912-026-01839-7

Abstract

PURPOSE OF REVIEW: Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma arising in apocrine gland-bearing skin, most commonly affecting the vulva. While non-invasive disease generally follows an indolent course with favorable prognosis, invasive locoregionally advanced or metastatic EMPD remains a major therapeutic challenge because of poor outcomes, lack of disease-specific guidelines, and limited efficacy of conventional systemic therapies. This unmet need supports a shift from empirical treatment toward biologically informed strategies. We performed a narrative review of PubMed and clinical trial registries to evaluate current therapies and emerging molecularly driven approaches, with particular focus on vulvar Paget disease (VPD). RECENT FINDINGS: Available evidence suggests that conventional cytotoxic chemotherapy offers only temporary disease control with limited durable benefit. In contrast, recent molecular and immunological discoveries are reshaping the therapeutic landscape. HER2 currently represents the most clinically actionable target, supported by a strong biological rationale, multiple clinical reports, and the best prospective evidence available to date. Other potential targets include immune-related biomarkers, steroid hormone receptor signaling, GLUT1, NECTIN4, tumor mutational burden, and selected histology-agnostic genomic alterations, highlighting the marked biological heterogeneity of EMPD. However, most evidence remains preclinical or derives from small case series. Immune checkpoint inhibitors have shown sporadic but clinically meaningful activity in selected patients, particularly in tumors with high tumor mutational burden, supporting biomarker-driven immunotherapeutic strategies. Advanced EMPD should be regarded not simply as a rare chemoresistant malignancy, but as a biologically heterogeneous disease requiring comprehensive pathological, immunohistochemical, and molecular characterization to guide future precision-based therapies.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.